Expression profiling of 21 biomolecules in locally advanced nasopharyngeal carcinomas of Caucasian patients by Dimitrios Krikelis et al.
Krikelis et al. BMC Clinical Pathology 2013, 13:1
http://www.biomedcentral.com/1472-6890/13/1RESEARCH ARTICLE Open Access, Vassilios Vassiliou
Expression profiling of 21 biomolecules in locally
advanced nasopharyngeal carcinomas of
Caucasian patients
Dimitrios Krikelis1*†, Mattheos Bobos2†, Georgia Karayannopoulou3, Liliana Resiga4, Sofia Chrysafi2,
Epaminontas Samantas5, Dimitrios Andreopoulos6 6, Elisabeta Ciuleanu4 and George Fountzilas1Abstract
Background: Since scarce data exist on the pathogenesis of nasopharyngeal carcinoma in Caucasian patients, we
attempted to elucidate the responsible molecular pathways in this patient population.
Methods: Formalin-fixed paraffin-embedded tumor tissue samples from 107 patients, diagnosed with
locally-advanced nasopharyngeal carcinoma and treated with chemotherapy or chemo-radiotherapy, were analyzed
by immunohistochemistry for the expression of the following proteins: E-cadherin, P-cadherin, Fascin-1, Cyclin D1,
COX-2, EGFR, VEGF-A, VEGF-C, VEGFR-2, VEGFR-3, ERCC1, p53, p63, Ki67, MAPT, phospho-p44/42MAPK, PTEN,
phospho-AKT, phospho-mTOR, and phospho-GSK-3β. EBER status was assessed by in situ hybridization. The majority
of the cases were included in tissue microarray. All stains were performed and assessed centrally by two
pathologists. The median follow-up time was 76.8 (42.3 – 99.2) months.
Results: Biomolecules expressed in >90% of cases were: p53, COX-2, P-cadherin, EBER, phospho-GSK-3β, and Fascin-
1. WHO II+III tumors were more frequently EBER & PTEN positive and VEGF-A negative. Advanced age was
significantly associated with positive phospho-GSK-3β and ERCC1 expression; male gender with positive
phospho-AKT and phospho-p44/42MAPK; and worse performance status (1 or 2) with negative Ki67, ERCC1, PTEN,
and phospho-mTOR expression. Earlier disease stage was closely associated with p63, MAPT, PTEN, and Cyclin D1
positivity. Univariate Cox regression analysis highlighted Cyclin D1 as a negative prognostic factor for disease-free
survival (p=0.034) and EBER as a positive one for overall survival (p=0.048). In multivariate analysis, advanced age
and stage, poor performance status, and positive ERCC1 emerged as predictors of worse disease-free and overall
survival, as opposed to positive phospho-mTOR. Clustering analysis defined two protein-expression groups being
predictive of better overall survival (p=0.043).
Conclusions: Our study is the first to examine the activation and interaction of established biomolecules and
signaling pathways in Caucasian NPC patients in an effort to reveal new therapeutic targets.
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Nasopharyngeal carcinoma (NPC) is unique in terms of
epidemiology, pathogenesis, and physical history com-
pared to the anatomically adjacent cancers of the head
and neck area. Approaching nasopharyngeal cancer as a
single entity is misleading, since it is comprised of separ-
ate histology subtypes characterized by variable radio-
and chemo-sensitivity, distinct prevalence patterns and
different outcome [1]. Particularly, the nonkeratinizing
undifferentiated subtype (WHO III) is endemic in southern
China and common in Asian and African regions; Epstein-
Barr virus (EBV) is implicated as the causal agent in the
vast majority of these cases, characterized by a favorable
prognosis. On the contrary, the keratinizing and the
nonkeratinizing differentiated variants (WHO I and II,
respectively) account together for 50%–75% of NPCs in
the United States [2].
Evolution of personalized medicine is widely acknowl-
edged as the only way to overcome the inherent limita-
tions of chemotherapy [3]. As a matter of fact, research
on the development of prognostic and predictive markers
in head and neck squamous cell carcinomas (HNSCC)
has led to the incorporation of cetuximab, an anti-EGFR
monoclonal antibody, into the contemporary therapeutic
management. However, these advances are not applicable
to NPC arena, for which translational research has not
yielded remarkable outcomes yet. As a result, NPC is still
managed as a homogeneous disease and the prognosis of
patients diagnosed in advanced stage remains poor [4].
Notably, the main bulk of research efforts originate from
the Far East, thus questioning the potential application of
any findings to NPC patients of Caucasian origin.
Building upon these prerequisites, our group performed
a comprehensive, mostly immunohistochemical (IHC),
expression profiling of 21 biomolecules from tumors of
locally advanced NPC (LA-NPC) Caucasian patients trea-
ted with chemotherapy or chemo-radiotherapy (CRT) in
the context of a Hellenic Cooperative Oncology Group
(HeCOG) randomized trial [5]. Biomolecules were selected
on the basis of a wide representation of signaling pathways
and processes critical in driving carcinogenesis, such as
angiogenesis, cell adhesion, assembly, proliferation and
differentiation, cell cycle and transcription regulation,
DNA repair, microtubule assembly, and inflammation
mediation.
To the best of our knowledge, this is the first report of
such a broad protein expression profiling in a consider-
able number of Caucasian NPC patients.
Methods
The clinical study – ethics approval
This is a translational study in LA-NPC patients per-
formed as an extension of a randomized trial, conducted
by HeCOG [5], which tested the addition of inductionchemotherapy (cisplatin 75 mg/m2, epirubicin 75 mg/m2
and paclitaxel 175 mg/m2 every 3 weeks) (patient Group
A) to the standard approach of concurrent chemo-
radiotherapy with cisplatin (patient Group B). The main
eligibility criteria were as follows: (i) biopsy-proven, pre-
viously untreated WHO type I, II or III NPC; (ii) age
>15 years; (iii) stage II–IVB according to the American
Joint Committee on Staging of Cancer classification
(AJCC 7th edition, 2009); (iv) measurable or evaluable
disease; (v) no other primary tumors; (vi) performance
status (PS) of 0–2 according to the Eastern Cooperative
Oncology Group (ECOG) scale.
Tissue paraffin blocks and peripheral blood for DNA
analysis were prospectively collected from each patient
registered in the study. The clinical protocol and collateral
translational research studies were approved by the
HeCOG Protocol Review Committee, the Institutional Re-
view Boards in participating institutions and the Bioethics
Committee of the Aristotle University of Thessaloniki
School of Medicine under the general title: “Investigation
of putative predictive or prognostic biomarkers in patients
with locally advanced nasopharyngeal carcinoma”. The
study was also registered at the Australian New Zealand
registry (ACTRN 12609000730202). Prior to randomization
each patient provided a study-specific written informed
consent and optionally a separate informed consent for the
provision of biological material for future research studies.
Tissue samples for molecular analysis
One hundred and nineteen formalin-fixed paraffin-em-
bedded (FFPE) tumor tissue samples from 118 patients
were available for analysis (only in one case, 2 samples
were examined from 1 patient). Eleven blocks were not
further evaluated due to inappropriate material (inad-
equate material in 7 cases and no tumor in 4 cases).
Thus, 108 samples from 107 patients were examined for
EBV-related small RNA (EBER) detection with the use
of chromogenic in situ hybridization (CISH) [6] and for
a number of key regulatory proteins by utilizing IHC
[7,8]. Finally, 105 samples from 105 patients were suc-
cessfully assessed with CISH and IHC (REMARK dia-
gram, Figure 1). Representative slides (hematoxylin and
eosin, H&E) from the tissue blocks were reviewed by an
experienced pathologist (M.B.) for confirmation of the
diagnosis and adequacy of material as well as calculation
of the percentage of tumor cells in each case. In 97 cases,
the tumor tissue in the paraffin block was adequate for the
construction of tissue microarrays (TMA), while for 11
cases all assays were performed on whole tissue sections.
TMA construction
Tumor tissue specimens were arrayed (3 cores per case,
0.6 mm in diameter) into a recipient paraffin block using a
manual arrayer (MTA-1, Beecher Instruments, Sun Prairie,
Randomized patients treated in cooperating centers, n=141 
119 FFPE tissue samplesfrom 118patients 
Adequate FFPE tissue samples from 107 patients
Inadequate material, n=7
No tumor, n=4
Successful CISH and IHC at least in one marker, n=105
Analyzed cases, n=105 (98%)
excluded
Figure 1 REMARK diagram of the study.
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tonsil, placenta, kidney, thyroid, breast, and prostate)
and cancerous tissues (melanoma, testicular seminoma,
colon carcinoma, squamous head and neck carcinoma,
and endometrial carcinoma) were also loaded on the TMA
block, serving as positive and negative assay controls.
Chromogenic in situ hybridization
In order to detect latent EBV infection [6], CISH assays
were performed on serial 4 μm-thick sections from the
original blocks and the TMA block, using a Bond Max™
autostainer (Leica Microsystems, Wetzlar, Germany), according
to the provider’s specifications as described in detail else-
where [5]. The poly-A probe, used as an indicator of the
preservation of mRNA in the cells (positive control),
resulted mainly in dark brown nuclear staining and less in a
cytoplasmic one.
Immunohistochemistry – selection of proteins
Immunohistochemical labelling was performed on serial
3 μm-thick sections from the original blocks and the
TMA block. Proteins involved in angiogenesis, cell adhe-
sion, assembly, proliferation and differentiation, cell cycle
and transcription regulation, DNA repair, microtubule as-
sembly, and inflammation mediation were investigated. A
list of the studied proteins, the sources of antigens and the
staining procedures for IHC and the cut-offs used [6-11]
are quoted in Table 1. The Multi-Cytokeratin (AE1/AE3)was used as a control stain for the identification of tumor
cells.
Evaluation of the CISH and IHC
The evaluation of CISH and IHC stained sections was
done simultaneously by two pathologists (G.K. and M.B.)
blinded as to the patients’ clinical characteristics and sur-
vival data, according to the criteria quoted in Table 1.
Tumor cells containing EBER transcripts were evaluated
as positive when an intense, brown, predominantly nuclear
staining was present in >1% of tumor cells [12]. Only
poly-A probe positive cases were evaluable for EBER sta-
tus. IHC cut-off values were defined prospectively, based
on distributional analyses in frequency histograms and the
medical literature. In order not to miss cut-off values with
prognostic utility, a Receiver-Operating Curve analysis of
IHC staining scores was followed with disease progression
as the indicator parameter; this analysis failed to show any
cut-off with significant sensitivity and specificity (Table 1).
Based on the selected IHC cut-offs, protein expression sta-
tus was defined for each tumor as either negative or posi-
tive, except for Ki67 which was graded as low (≤13%) or
high (>13%). Representative cases of CISH and IHC stain-
ing are presented in Additional file 1: Figure S1.
Image analysis
Stained sections for Cyclin D1 and Ki67 were evaluated
using an image analysis system as described [5]. The cut-
Table 1 Studied proteins, primary antibodies, source and dilutions of antibodies, staining patterns, and interpretation
(cut-off) criteria used in the present study







E-cadherin HECD-11 1:30 20 min / ER1 60 min IRS ≥5 C, C/M
P-cadherin 562 1:200 20 min / ER2 O/N IRS ≥5 C, C/M
Cell assembly molecules
Fascin-1 IM201 1:400 20 min / ER1 O/N 5% C
Cytokeratin Multi AE1/AE31 1:100 10 min / Enzyme 1 20 min 1% C
Cell cycle regulators
Cyclin D1 SP43 1:80 20 min / ER1 30 min IA (5%) N
Cell growth molecules
VEGF-A VG14 1:75 20 min / ER2 60 min 5% C
VEGF-C 18-2255, pl5 1:250 20 min / ER1 O/N 5% C
Phospho-mTORSer2448 49 F96 1:30 20 min / ER1 20 min 5% C, C/PN
Cell proliferation molecules
Ki67 MIB14 1:70 15 min / ER2 20 min IA (13%) N
Cell receptors
EGFR 31 G75 1:50 8 min / Enzyme 2 20 min 10% M, C/M
VEGFR-2 55B116 1:450 20 min / ER2 O/N 5% C, C/N
VEGFR-3 KLT91 1:50 15 min / ER1 O/N 5% C
DNA repair molecules
ERCC1 8 F12 1:300 15 min / ER2 30 min 50% N, C/N
p53 DO-74 1:100 20 min / ER1 20 min 50% N, N/C
Inflammation mediators
COX-2 4H121 1:300 20 min / ER1 O/N IRS≥3 C
Microtubule assembly
MAPT (Tau) 2B2.1007 1:100 20 min / ER1 O/N 5% C, N, C/N
Molecules with kinase activity
Phospho-AKTSer473 D9E6 1:150 20 min / ER2 O/N 5% C, N, C/N
Phospho-GSK-3βSer9 5B36 1:50 20 min / ER1 O/N 5% C, N, C/N
Phospho-p44/42
MAPKThr202/Tyr204
20 G116 1:1000 20 min/ ER1 O/N 5% C, N, C/N
Transcriptional activator or
repressor
p63 4A41 1:50 20 min / ER2 60 min 5% N
Tumor suppressor
PTEN 6H2.14 1:300 20 min / ER2 60 min 10% C, N, C/N
1Leica Biosystems, Newcastle, UK; 2Thermo Fisher Scientific, Fremont, CA;3Spring Bioscience, Pleasanton, CA; 4Dako, Glostrup, Denmark; 5Invitrogen, Carlsbad, CA;
6CST: Cell Signaling Technology, Danvers, MA; 7United States Biological, Swampscott, MA.
ER1: Epitope Retrieval 1 (citric acid, pH 6); ER2: EDTA (pH 8.8); IA: image analysis; IRS: immunoreactive score=Intensity (0–3) +% of stained cells (0:0-5%, 1:6-25%,
2:26-50%, 3:>50%); min: minutes; M: membrane; N: nuclear; O/N: overnight; pl: polyclonal; PN: perinuclear; C: cytoplasm; C/M: cytoplasm/membrane.
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are quoted in Table 1.
Statistical analysis
Categorical data are displayed as frequencies and corre-
sponding percentages, while continuous data by medianand range. For the comparison of continuous data the
non-parametric Kruskall Wallis test was used, while the
comparison of categorical data between groups was per-
formed by Fisher’s exact or Pearson chi-square tests,
where appropriate. Overall survival (OS) was measured
from the date of treatment randomization to patient’s
Table 2 Patient demographics and disease characteristics
Age (years)
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http://www.biomedcentral.com/1472-6890/13/1death or last contact. Progression-free survival (PFS) was
measured from the date of treatment randomization to
documented disease progression, death without prior
documented progression or last contact. Time-to-event
distributions were presented using Kaplan-Meier curves
and compared using the log-rank test. Unsupervised hier-
archical clustering analysis using the majority of the exam-
ined biomarkers was conducted. Univariate Cox regression
analyses were performed for OS and PFS, to assess the
prognostic or predictive significance of biomarkers adjusted
for treatment. A backward selection procedure with a re-
moval criterion of p>0.10 was performed in the multivari-
ate Cox regression analysis in order to identify significant
factors among examined biomarkers, basic clinicopatholo-
gical characteristics (categorized as given in Additional
file 2: Table S1) and treatment group. For all comparisons
the level of significance was set at α=0.05. All results are
presented according to reporting recommendations for
tumor marker prognostic studies [13]. Analyses were
performed with the use of the SPSS v. 17.0 (SPSS, Inc.,
Chicago, IL), JMP version 8 and SAS version 9.3 (SAS,









Type I 10 9.3
Type II 21 19.6









Patient and tumor characteristics – survival times
Selected patient and tumor characteristics are quoted in
Table 2. The male/female ratio was 2.24/1. The majority of
patients were of PS 1 or 2, early T stage and advanced
lymphnode involvement. Findings deserving closer atten-
tion are the normal pattern of age distribution (Figure 2)
and the relatively low incidence of WHO Type I disease,
given that the population was Caucasian (9.3%).
The patients have been followed for an additional period
of 21.8 months compared to the respective clinical study
[5]. After a median follow-up time of 76.8 months (range
42.3-99.2 months), 3-year PFS and OS rate for all patients
in the study were 60.7% and 66.4%, respectively. Mean PFS
and OS for all patients were 49.7 months and 52.9 months,
respectively. No statistically significant differences emerged
when time-to-event times were analyzed with respect to
the treatment group (mean PFS: 51.1 months for Group
A vs. 47.4 months for Group B, p = 0.65; mean OS:
53.4 months for Group A vs. 51.7 months for Group B,
p = 0.938).<12 94 87.9
Unknown 3 2.8
Best Response Group A Group B
CR 42 58 38 55
PR 18 25 21 30
ORR 60 83 59 85
SD 3 4 2 3Frequency of IHC marker expression
Biomarkers with the most frequent expression (>90% posi-
tive cases) were: p53, COX-2, P-cadherin, EBER, phospho-
GSK-3β (p-GSK-3β), and Fascin-1. On the contrary, the
least IHC-expressed proteins (<50% positive cases) were
as follows: VEGFR-2, phospho-mTORSer2448 (p-mTOR),
VEGF-A, and p16 (Table 3).
Table 2 Patient demographics and disease characteristics
(Continued)
PD 2 3 5 7
NE 7 10 3 4
CR: complete response; PR: partial response; ORR: overall response rate; SD:
stable disease; PD: progressive disease; NE: not evaluated.
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characteristics and response to treatment
The statistically significant correlations of patients’ clini-
copathological characteristics with the IHC proteins ex-
pression are presented in Additional file 2: Table S1.
Notably, PTEN and p63 expression patterns were clearly
linked with favorable characteristics: patient PS and T
stage (for the former), T and AJCC TNM stage (for the lat-
ter). Positive phospho-AKT (p-AKT) and phospho-p44/
42MAPK (p-MAPK) expression were related to male gen-
der, positive p-GSK-3β and ERCC1 expression depicted a
more advanced age at diagnosis, and deficiency of ERCC1
and p-mTOR expression were correlated to poor patient
PS. As expected, positive EBER expression status was
linked to WHO Type III histology. Unexpectedly, Ki67-
positive tumors were more frequently associated with
earlier N stage and good PS; likewise, Cyclin D1 expres-
sion was more often positive in tumors of earlier AJCC
TNM stage.
Associations between the expression status of the tested
biomarkers and response to treatment did not reveal sig-
nificant predictive values for any of them (Data not shown).
Paired associations of protein expression as detected by
IHC
Additional file 3: Table S2 presents all statistically signifi-
cant paired associations of protein IHC expression. TheFigure 2 Age distribution frequencies of the studied nasopharyngealmost interesting paired interactions were as follows: p63/
p-AKT, p63/Ki67, p-AKT/Ki67, p-AKT/ERCC1, Ki67/
ERCC1, Ki67/PTEN, Ki67/Cyclin D1, p-mTOR/ERCC1,
and p-mTOR/VEGFR3.
Consequently, the most informative biomarkers in NPC
with regards to IHC expression were: p63, p-AKT, Ki67,
ERCC1, CyclinD1, p53, COX-2, and p-mTOR.
Profiling cluster models of protein expression
In an effort to study the complex interactions among the
examined biomarkers, cluster analysis of the IHC pro-
tein expression was performed.
Firstly, all protein targets were included in the analysis
and gradually increasing numbers of clusters were tested
for their prognostic significance with respect to PFS and
OS as well as their association with T and N status,
AJCC TNM stage, and overall response rate (ORR) to
treatment. The only model with prognostic significance
was a 2-cluster one, with a borderline association to fa-
vorable OS (p=0.048) (Figures 3 and 4) and earlier TNM
stage (p=0.027 for stage IIB-III vs. IV). Cluster analysis
for each of the two treatment groups (A and B) did not
result in the emergence of any meaningful prognostic
significance.
A following step was to look at a more compact set of
protein targets (such as p-AKT, p-mTOR, PTEN, VEGF-A,
ERCC1, and p53) based on their relative significance in
driving carcinogenesis or their possible synergistic action.
In this case, no cluster appeared to confer prognostic infor-
mation for any of the endpoints tested.
Univariate analysis
In univariate Cox regression analysis adjusted for treat-
ment, the only biomarkers with positive prognostic valuepatient population.
Table 3 Frequency of immunohistochemical expression of the examined biomarkers in nasopharyngeal carcinoma
(sorted from the most frequently expressed to the least frequently ones)
Biomarker No of Cases Positive (%) Negative (%)
Multi-Cytokeratin 103 102 (99) 1 (1)
COX-2 94 90 (95.7) 4 (4.3)
P-cadherin 97 92 (94.8) 5 (5.2)
EBER 101 94 (93.1) 7 (6.9)
Phospho-GSK-3βSer9 100 92 (92) 8 (8)
Fascin-1 96 88 (91.7) 8 (8.3)
E-cadherin 94 83 (88.3) 11 (11.7)
p63 94 83 (88.3) 11 (11.7)
EGFR 95 83 (87.4) 12 (12.6)
p53 95 82 (86.3) 13 (13.7)
Phospho-AKTSer473 96 79 (82.3) 17 (17.7)
Ki67 100 78 (78) 22 (22)
ERCC1 105 78 (74.3) 27 (25.7)
MAPT (Tau) 104 74 (71.2) 30 (28.8)
VEGF-C 100 64 (64) 36 (36)
Phospho-p44/42 MAPKThr202/Tyr204 95 60 (63.2) 35 (36.8)
PTEN 102 64 (62.7) 38 (37.3)
VEGFR-3 101 60 (59.4) 41 (40.6)
Cyclin D1 102 53 (52) 49 (48)
VEGFR-2 95 44 (46.3) 51 (53.7)
Phospho-mTORSer2448 101 38 (37.6) 63 (62.4)
VEGF-A 100 36 (36) 64 (64)
p16 105 5 (4.8) 100 (95.2)
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the premature translational analysis of the relevant clin-
ical study [7]. Particularly, EBER expression was linked
to a favorable OS in a statistically significant way (hazard
ratio HR = 0.38, 95% CI = 0.15-0.99, p = 0.048), while its
association to improved PFS was only of borderline sig-
nificance (HR = 0.44, 95% CI = 0.17-1.14, p = 0.09). The
favorable prognostic value of positive p63 expression
was borderline only for OS (HR = 0.48, 95% CI = 0.21-
1.09, p=0.08) (Table 4 and Additional file 4: Figures S2).
Of special interest was the predictive significance of
Cyclin D1 expression, which emerged only when the
patient population was adjusted for the administered
treatment (Group A vs. Group B). In this case, immu-
nopositivity for Cyclin D1 resulted in a statistically sig-
nificant worse prognosis in terms of PFS for patients
in Group B (HR = 2.64, 95% CI = 1.08-6.48, p=0.034)
(Table 4), while the absence of Cyclin D1 expression
conferred a trend of better OS for the same Group
(HR = 0.44, 95% CI = 0.18-1.04, p=0.062) (Table 4). Log-
Rank test was subsequently performed, which confirmedthe results of Cox regression analysis mentioned above
(Figures 5A and 5B).
Multivariate analysis
The following parameters were pointed out by multivari-
ate analysis as the significant prognostic indicators for
both PFS and OS: age at diagnosis, treatment group, PS,
AJCC TNM stage, p-mTOR and ERCC1 expression. Not-
ably, not only the same variables were indicated as import-
ant for both PFS and OS, but also the magnitude of
significance (denoted by HR value) was similar in both
conditions (Tables 5 and 6).
Particularly, advanced age, the addition of induction
chemotherapy, poor PS, AJCC stage IV, and positive ERCC1
expression were associated with a higher probability of
disease progression and death. On the contrary, positive
p-mTOR expression was related to a decreased risk of
progression and death (Additional file 4: Figures S2).
Compared to the preliminary analyses performed in
the context of the respective clinical study [7], Ki67 and
p63 lost their independent prognostic value in the longer
Figure 3 Hierarchical clustering analysis of the studied biomolecules in nasopharyngeal carcinoma. Red and green signals indicate cases
with increased and decreased protein expression, respectively; white signals indicate missing cases. Two clusters are distinguished, red and green,
with different predominant patterns of protein expression.
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Red Cluster: predominantly increased protein expression
Green Cluster: predominantly decreased protein expression
p=0.048
Figure 4 Prognostic significance for overall survival of the red
and green clusters, with predominantly increased and
decreased protein expression, respectively.
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which maintained their significance.
Discussion
In contrast to the progress seen in the molecular classifi-
cation, pathogenesis elucidation and management of quite
a few neoplasms, little has been achieved towards persona-
lized approach in the NPC field so far. In contrast to the
paradigm of other neoplasms, no activating mutations,
such as EGFR or PI3K, are known to drive nasopharyngeal
carcinogenesis [14,15]. It seems that nasopharyngeal car-
cinogenesis is far more composite than the almost ubiqui-
tous EBV presence depicts. As a result, survival rates of
patients with advanced disease remain poor, especially for
non-endemic populations [16]. During the last few years,
we have witnessed combined efforts to unravel NPC
pathogenesis by utilization of multiple gene expression











Group B vs. Group A 0.44 0.18-1.04
Positive
Group B vs. Group A 2.02 0.81-5.07molecular or cytokine markers, integration of miRNA
technologies, and exploration of epigenetics.
The present study incorporates novel features which
differentiate it from the rest utilizing IHC in NPC. In
particular, 21 protein targets have been simultaneously
profiled for their expression levels in nasopharyngeal
tumors, in order to observe possible cross-talks between
pathways. Biomarkers were carefully chosen, in order to
include representatives from as many as possible onco-
genic processes, as reviewed recently [17]. In view of
this, the clustering analysis performed is considered even
more informative. More importantly, the study popula-
tion was a Caucasian one, representing not only the
entire Greek region but also the Balkan Peninsula, since
HECOG-affiliated hospitals from both Greece and Romania
have participated in this study. Although a considerable
number of Caucasian NPC patients have been studied dur-
ing the last decades [18-23], the respective series have either
focused just on clinical parameters or have investigated only
a limited number of biomarkers.
The high frequency of EBER CISH expression was not
surprising, even for the Caucasian population of our
study, as EBV infection is almost ubiquitous globally and
plays a major role in the pathogenesis of NPC in both
endemic and non-endemic areas [1]. Generally, our study
confirmed that the well-established characteristics of EBV-
related NPC are also applicable to Caucasian NPC patients.
Namely, the strong connection of EBV to WHO Type II
and III histology as well as to the more favorable disease
course [24]. Importantly, the univariate analysis indi-
cated EBER expression as a significant prognostic factor
of improved OS.
Cyclin D1 is one of the key proteins involved in cell
cycle control, a process considered as critical in the de-
velopment of NPC [25]. Although our study did not find
as high uniform Cyclin D1 expression as reported in the
literature [7], IHC expression levels were interestinglybiomarkers adjusted for treatment
PFS
Wald’s p HR 95% CI Wald’s p
1
0.048 0.44 0.17-1.14 0.09
1
0.08 0.56 0.25-1.28 0.17
0.062 0.5 0.22-1.16 0.11
0.13 2.64 1.08-6.48 0.034
A B
Figure 5 Prognostic significance of Cyclin D1 expression. Log-Rank test for the effect of Cyclin D1 expression on progression-free and overall
survival, stratified by treatment group (Group A: patients treated with induction chemotherapy followed by concurrent chemo-radiotherapy;
Group B: patients treated with concurrent chemo-radiotherapy only); (A) positive and (B) negative Cyclin D1 expression.
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between Cyclin D1 and Ki67 as well as between Cyclin D1
and p-AKT expression was indicated, pointing to an active
cell proliferation axis, which has already been investigated
as a therapeutic target in NPC [26]. More importantly,
univariate analysis pointed to a predictive role for Cyclin
D1 protein levels, as differences in PFS and OS emerged
only when the study population was adjusted for treat-
ment. In particular, patients treated with induction
chemotherapy prior to chemo-radiotherapy fared sig-
nificantly better (in terms of PFS) in the case of positive
Cyclin D1 expression, while in the absence of Cyclin D1
this finding was inverted (for OS). Consequently, it
seems that tumors with enhanced Cyclin D1 function
are vulnerable to more aggressive treatment. This result
is in fine agreement with the reported radio-sensitivity
of Cyclin-enriched nasopharyngeal [7], laryngeal [27],
and breast [28] cancers.
The function of p63, a transcription factor and member




Group B vs. Group A 0.41 0.33
PS
1-2 vs. 0 1.5 0.41
Stage
IV vs. II-III 0.95 0.33
p-mTOR
Positive vs. Negative −0.8 0.33
ERCC1
Positive vs. Negative 1.02 0.41major classes of p63 isoforms have been identified: the
full-length TAp63 and the N-terminal truncated ΔNp63
[29]. The two isoforms exert opposite purposes; TAp63
isoform has similar function to the wild-type p53 protein,
while ΔNp63 is thought to antagonize TAp63 and p53 in
target gene regulation. Each isoform can be targeted by a
specific antibody for IHC evaluation, while a pan-p63
one binds to common epitopes. Consequently, reports
of overexpression and oncogenic properties of p63 in
NPC [30,31] should be construed through this prism,
also bearing in mind that the predominant isoform is
the truncated ΔNp63 one. In our study, a pan-p63 anti-
body was utilized, thus limiting the importance of the
borderline favorable prognostic value for OS, which emerged
for p63 in the univariate analysis. Accordingly, the strong
correlation of p63 expression with p-AKT and Ki67 as
well as its association with early disease stage should be
interpreted with caution.
The virtual absence of p16 IHC expression in our







Table 6 Multivariate Cox model for overall survival
Parameter Estimate Standard Error p-value HR 95% CI
Age 0.047 0.011 <0.001 1.048 1.024-1.073
Group
Group B vs. Group A 0.23 0.33 0.5 1.25 0.66-2.40
PS
1-2 vs. 0 1.4 0.42 <0.001 4.06 1.79-9.19
Stage
IV vs. II-III 0.92 0.34 0.007 2.5 1.28-4.89
p-mTOR
Positive vs. Negative −0.76 0.38 0.044 0.47 0.22-0.98
ERCC1
Positive vs. Negative 0.93 0.42 0.028 2.54 1.11-5.81
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mainly to aberrant methylation or even to gene deletion.
In contrast to reports supporting a predictive role of p16
to both chemotherapy (5-flouoruracil and cisplatin) [33]
and radiotherapy [34], our study did not find any con-
nection of p16 protein expression with disease outcome.
Likewise, despite the documented unfavorable value of
p16 expression in NPC [7,35], such a role did not emerge
in our study. The inevitable small number of p16-positive
cases undoubtedly calls for a cautious reading of these
results.
Activation of the PI3K/AKT/mTOR pathway has been
reported in NPC several years ago [36]. AKT phosphor-
ylation can be either a result of LMP1 [37] or EGFR [14]
action on PI3K or a compensatory consequence of decreased
PTEN levels [38]. However, EBER/p-AKT or EGFR/p-AKT
protein interactions did not emerge in our study. More-
over, the comparable expression levels of p-AKT and
PTEN argue in favor of a downward activation of AKT
instead of a compensatory one. p-AKT association with
the Ki67 status may reflect the known propensity of
AKT-activated NPC to metastasize [39]; however, we could
not confirm the contribution of decreased E-cadherin levels
to this phenomenon [40].
Cadherin IHC expression did not acquire any signifi-
cance in our study with regard to disease prognosis or
association with the rest biomolecules examined. Despite
the reported depletion of E-Cadherin expression in NPC
tissues in comparison to the normal ones [32,41], a high
level of IHC expression was observed in our study, both
for P- and for E-Cadherin. One possible explanation is the
low IHC cut-off that was selected, compared to other
reports [42]. On the other hand, the enhanced Cadherin
expression might not merely be an artifact but could
reflect a lack of its contribution to NPC pathogenesis
in Caucasian patients. Such a scenario would justify the
absence of any unfavorable prognostic value, contraryto reports of low tumor Cadherin levels in NPC patients
with advanced disease stage and decreased survival [43].
The predictive role of high ERRC1 protein levels to
cisplatin-containing regimens has been firstly described
in ovarian cancer 20 years ago [44]. However, it was only
recently that similar reports were published in NPC
[45]. In line with this evidence, multivariate analysis in
our study showed a significant unfavorable association
of increased ERCC1 expression with both PFS and OS.
Since cisplatin was the chemotherapy backbone in both
patient groups, this outcome could be explained as a
negative predictive effect of high ERCC1 protein levels.
In addition, a poor prognostic value of ERCC1 could also
be contemplated, as increased ERCC1 protein levels were
significantly associated with aggressive disease characteris-
tics, such as positive Ki67 and p-AKT IHC expression.
Loss of PTEN expression is a frequent event in NPC
[46], accounting for the extensive deregulation of cellular
signaling pathways (e.g. PI3K/AKT/mTOR and Wnt) and
the metastatic propensity via induction of the epithelial-
mesenchymal transition phenotype. Our study, in line with
the literature evidence, has found a relatively low rate of
PTEN expression. Moreover, PTEN presence was signifi-
cantly associated with early tumor stage, a finding which
has been also described in Chinese NPC patients [47].
Increased COX-2 IHC expression in NPC has been
linked to the presence of lymph node metastasis [48] and
worse survival, as well to enhanced sensitivity to the radio-
therapy effects [49]. In contrast to such well-established
evidence, no prognostic or predictive role for COX-2 was
revealed in our study, despite the higher COX-2 expres-
sion frequency compared to previous reports [50]. How-
ever, in line with our observations are a few studies [51]
which indicate no prognostic significance of COX-2 or
even a positive one [52], thus perplexing COX-2 contri-
bution to NPC pathogenesis. Commonly reported co-
expression patterns, such as COX-2/EGFR/VEGF [53],
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confirmed in the present study. The axis LMP1/COX-2/
VEGF [56], in which COX-2 is promoted by LMP1 and
subsequently induces VEGF, was also not manifested in
our Caucasian patient series.
However extensive our investigation was, a bunch of
biomolecules and processes were not shown to contribute
in any way to NPC pathogenesis, despite the strong litera-
ture evidence to the contrary. In particular, p-MAPK was
neither evident in our tumor series nor was clinically
significant, counter to reports of an activated and tumor-
promoting MAPK in NPC [57]. Likewise, despite p-GSK-
3β being reported as a vital member of the PI3K/AKT/
GSK-3β/Cyclin D1 pathway in NPC promotion [26,36,46],
the present study did not result in such evidence. Simi-
larly, p53 expression was not informative in terms of dis-
ease prognosis or interaction with any other biomarker.
Several reports state the overexpression or accumulation
of p53 protein in the vast majority of NPC [58] and a
resulting tumor-promoting role ; however, p53 expression
was not detected to that extent in our study. Anyway,
the functional status of p53 is disputable in NPC [59],
which could explain the absence of its prognostic value
[59], as indicated also in our study. The antagonizing ef-
fect of ΔNp63 protein on p53, as quoted above, renders
the conclusion-making procedure even more insecure.
Fascin, an actin cross-linking protein, has been implicated
in the progression of various neoplasms, including NPC,
mainly through the promotion of cell migration and adhe-
sion [60]. In spite of Fascin’s high expression frequency in
our study, any significant correlation of Fascin-1 to NPC
pathogenesis cannot be implied.
The absence of any prognostic role for EGFR in our
Caucasian population, despite its high expression frequency,
is a result which needs particular consideration. There is a
substantial bulk of evidence concerning the unfavorable
prognostic value of EGFR both for disease stage and for
outcome [61], even in Caucasian populations [62], the only
exception being a recent Korean study [51]. Additionally,
several co-expression patterns have been described, such as
EGFR/COX-2 [53,54], EGFR/VEGF [53], and EGFR/AKT
[14], not being manifested in our series. Although EBV
presence is believed to induce EGFR [63], such a paired ex-
pression model was also not found. The paucity of EGFR-
expression information in the present study could be
interpreted in the context of the evolving understanding
of EGFR role in NPC pathogenesis; EGFR downstream
signaling molecules are numerous in NPC and are still
being defined [64]. The relative inefficacy of EGFR-
targeting attempts in NPC [65], in contrast to HNSCC
[66], serves as a reminder of the underlying complexity.
VEGF-A and -C expression status were also not inform-
ative with regard to prognosis or any association with clini-
copathological variables. In spite of the abundant literaturereferences of an adverse prognostic role of VEGF expres-
sion in NPC [67,68] and VEGF-C in particular [69], no
such effect was shown. Furthermore, several co-expression
pairs have been repeatedly described, mainly between VEGF,
COX-2, EGFR, and LMP1 [56,70], which were not prom-
inent in our tumor series. Anyway, the exact setting in
which angiogenesis exerts its tumor-promoting action
needs to be clarified, as depicted by the modest results of
anti-angiogenic therapy so far [71].
Phosphorylated-mTOR expression emerged as an in-
dependent favorable prognostic factor in multivariate
analysis, although with borderline significance. mTOR is
linked with a promoting role in nasopharyngeal carcino-
genesis [72] and a unanimous adverse prognostic value
in NPC [73], which is alleviated by mTOR inhibition
[38]; thus, the aforementioned result is considered as
unexpected. Possible hypotheses for this discrepancy are:
a) the presence of p53 expression in all p-mTOR tumors
could account for a favorable outcome upon treatment
and b) multiple comparisons in a sample underpowered
for such exhausting statistical analyses could lead to an
artifact. Similarly, the association of increased Ki67 with
an earlier N stage and good PS is rather surprising and
could be attributed either to a statistical artifact, as
mentioned above, or to the IHC cut-off level which have
been used.
Clustering analysis did not reveal any discriminator group
of genes/biomolecules which could portray a specific driv-
ing scenario of carcinogenesis in NPC. Moreover, no NPC
subtype emerged on the basis of differential protein expres-
sion, which could point towards potential therapeutic
targets. Following the breast cancer paradigm [74], the
reported gene-profiling approaches in NPC end up to
different gene sets [75,76], calling once again for the need
of bioinformatics implementation to data interpretation.
It should be noted that the reported high frequency of
WHO Type I NPC histology in Caucasian populations
(approximately 25%) [2] was not represented in our study
(only 9%). Possibly, Balkan NPC patients represent an
intermediate population in terms of epidemiology, as
Balkan Peninsula shares the Mediterranean Basin and
neighbors to North Africa, which is a known endemic
NPC area.
The results of the present study should be interpreted
on the notion of the inherent limitations of IHC. Protein
expression levels often mirror the mechanisms leading
to cellular growth deregulation; however, they have to be
translated along with the coexisting genetic and epigen-
etic alterations. Moreover, clustering analysis is unable
to provide a perfect outline of the complex interactions
between the tumor-promoting networks; small-size sam-
ples and multiple comparisons undermine the validity of
the results. Last but not least, since several phospho-
antibodies were utilized, consideration should be paid to
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epitopes [77].
Conclusions
Despite the existence of published evidence to the con-
trary, the extensive IHC study and profiling of a broad
variety of biomolecules did not result in tangible conclu-
sions for many of them. However, our study came to
conclusions which could represent a step forward in dis-
closing the pathogenesis of NPC in Caucasian popula-
tions. The favorable prognostic value of EBER and p63,
the treatment-dependent prognostic significance of Cyclin
D1, as well as the independent prognostic value of ERCC1
and p-mTOR protein levels could be pointed as the most
interesting ones. What lies ahead is the prospective valid-
ation of these biomarkers and, hopefully, a meaningful
benefit for NPC patients.
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expression with clinicopathological parameters.
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mTOR, ERCC1 and Cyclin D1 protein expression for progression-free and
overall survival (Log-Rank test). For Cyclin D1, all patients have been
included, irrespective of the treatment administered.
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